UPDATE: RBC Capital Starts Gemphire Therapeutics (GEMP) at Outperform

August 30, 2016 6:40 AM EDT
Get Alerts GEMP Hot Sheet
Price: $10.32 -1.24%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade GEMP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - August 30, 2016 7:41 AM EDT)

RBC Capital initiated coverage on Gemphire Therapeutics (NASDAQ: GEMP) with an Outperform rating and a price target of $25. Analyst Adnan Butt sees potential for significant upside.

"We initiate coverage with an Outperform rating and $25 price target. Gemcabene is differentiated and lowers both cholesterol and triglyceride levels to address cardiovascular diseases affecting 16M patients in the U.S. alone. Phase 2b trials are ongoing and could have data in 2017. GEMP has development flexibility, multiple paths to maximize gemcabene opportunity, owns all rights, and there is scarcity value for cardiovascular assets," said Butt.

For an analyst ratings summary and ratings history on Gemphire Therapeutics click here. For more ratings news on Gemphire Therapeutics click here.

Shares of Gemphire Therapeutics closed at $10.15 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

RBC Capital

Add Your Comment